The U.S. Food and Drug Administration approved Allergan’s Durysta (bimatoprost implant) 10 mcg for intracameral administration to treat open-angle glaucoma (OAG) or ocular hypertension.

The U.S. FDA approved the New Drug Application of Xelpros 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Mallinckrodt plc will acquire Sucampo Pharmaceuticals Inc., including its commercial and development assets.